Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

3.

Comment on the cylindrical capacitor electrospray interface.

König S, Fales HM, Haegele KD.

Anal Chem. 1998 Oct 15;70(20):4453-5.

PMID:
9796428
4.
5.

Evidence for a novel pentyl radical adduct of the cyclic nitrone spin trap MDL 101,002.

Dage JL, Ackermann BL, Barbuch RJ, Bernotas RC, Ohlweiler DF, Haegele KD, Thomas CE.

Free Radic Biol Med. 1997;22(5):807-12.

PMID:
9119249
6.

Simultaneous measurement of dolasetron and its major metabolite, MDL 74,156, in human plasma and urine.

Huebert ND, Schwartz JJ, Zeidler L, Schwach V, Haegele KD.

J Chromatogr B Biomed Appl. 1996 Oct 25;685(2):291-7.

PMID:
8953170
7.
8.

Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.

Dow J, Dulery BD, Hornsperger JM, Di Francesco GF, Keshary P, Haegele KD.

Arzneimittelforschung. 1995 Dec;45(12):1245-52.

PMID:
8595078
9.

Selectivity of MDL 72,974A for MAO-B inhibition based on substrate and metabolite concentrations in plasma.

Huebert ND, Schwach V, Hinze C, Haegele KD.

Prog Brain Res. 1995;106:135-42.

PMID:
8584649
10.

Metabolism and pharmacokinetics of the cardiotonic agent piroximone and of its major metabolite in dog.

Berg-Candolfi M, Dulery B, Jehl F, Haegele KD.

Xenobiotica. 1995 Jan;25(1):59-70.

PMID:
7604607
11.
12.

pNAT and CYP2D6 gene polymorphism in epileptic patients.

Borlak JT, Harsany V, Schneble H, Haegele KD.

Biochem Pharmacol. 1994 Nov 1;48(9):1717-20.

PMID:
7980640
13.

Kinetics and metabolism of p-tyramine during monoamine oxidase inhibition by mofegiline.

Huebert ND, Dulery BD, Schoun J, Schwach V, Hinze C, Haegele KD.

Clin Pharmacol Ther. 1994 Nov;56(5):537-42.

PMID:
7955818
14.

Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.

Dow J, Piriou F, Wolf E, Dulery BD, Haegele KD.

Drug Metab Dispos. 1994 Sep-Oct;22(5):738-49.

PMID:
7835226
15.

The measurement of beta-phenylethylamine in human plasma and rat brain.

Huebert ND, Schuurmans Schwach V, Richter G, Zreika M, Hinze C, Haegele KD.

Anal Biochem. 1994 Aug 15;221(1):42-7.

PMID:
7985801
17.

Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-beta-fluoromethylene benzene butanamine in man.

Dulery BD, Schoun J, Zreika M, Dow J, Huebert N, Hinze C, Haegele KD.

Arzneimittelforschung. 1993 Mar;43(3):297-302.

PMID:
8489556
18.

MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.

Palfreyman MG, McDonald IA, Zreika M, Cremer G, Haegele KD, Bey P.

J Neural Transm Suppl. 1993;40:101-11.

PMID:
8294896
20.

Assessment of the biotransformation of the cardiotonic agent piroximone by high-performance liquid chromatography and gas chromatography-mass spectrometry.

Berg-Candolfi M, Borlakoglu JT, Dulery B, Jehl F, Haegele KD.

J Chromatogr. 1992 Feb 28;593(1-2):1-7.

PMID:
1639892
21.
22.

Effects of a standardized meal on the pharmacokinetics of the new cardiotonic agent piroximone.

Haegele KD, Hinze C, Joder-Ohlenbusch AM, Cremer G, Borlak J.

Arzneimittelforschung. 1991 Dec;41(12):1225-9.

PMID:
1815521
24.

Cardioselectivity of alpha-tocopherol analogues, with free radical scavenger activity, in the rat.

Dow J, Petty MA, Grisar JM, Wagner ER, Haegele KD.

Drug Metab Dispos. 1991 Nov-Dec;19(6):1040-5.

PMID:
1687008
25.

A single-dose-finding study of the antiemetic effect and associated plasma levels of MDL 72222 in patients receiving cisplatin.

Logue J, Wilkinson P, Haegele KD, Orwin J.

Cancer Chemother Pharmacol. 1991;27(6):472-6.

PMID:
2013117
26.

A cardioselective, hydrophilic N,N,N-trimethylethanaminium alpha-tocopherol analogue that reduces myocardial infarct size.

Grisar JM, Petty MA, Bolkenius FN, Dow J, Wagner J, Wagner ER, Haegele KD, De Jong W.

J Med Chem. 1991 Jan;34(1):257-60.

PMID:
1992125
28.

Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid.

Ben-Menachem E, Persson LI, Mumford J, Haegele KD, Huebert N.

J Child Neurol. 1991;Suppl 2:S11-6.

PMID:
1719063
29.

Comparative aspects on the bioaccumulation, metabolism and toxicity with PCBs.

Borlakoglu JT, Haegele KD.

Comp Biochem Physiol C. 1991;100(3):327-38. Review. No abstract available.

PMID:
1687525
30.

Review: Normal and abnormal central nervous system GABA metabolism in childhood.

Jaeken J, Casaer P, Haegele KD, Schechter PJ.

J Inherit Metab Dis. 1990;13(6):793-801. Review.

PMID:
2079831
31.

[African trypanosomiasis in children treated with eflornithine. A case].

Benhamou PH, Chandenier J, Schechter PJ, Epelbaum S, Tell GP, Haegele KD, Pautard JC, Piussan C.

Presse Med. 1989 Jun 17;18(24):1199-202. French.

PMID:
2525760
32.

Cerebrospinal fluid parameters in healthy volunteers during serial lumbar punctures.

Ben Menachem E, Persson L, Schechter PJ, Haegele KD, Huebert N, Hardenberg J.

J Neurochem. 1989 Feb;52(2):632-5.

PMID:
2463340
33.

Phase I study of methylacetylenic putrescine, an inhibitor of polyamine biosynthesis.

Cornbleet MA, Kingsnorth A, Tell GP, Haegele KD, Joder-Ohlenbusch AM, Smyth JF.

Cancer Chemother Pharmacol. 1989;23(6):348-52.

PMID:
2713957
34.

The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients.

Ben-Menachem E, Persson LI, Schechter PJ, Haegele KD, Huebert N, Hardenberg J, Dahlgren L, Mumford JP.

Br J Clin Pharmacol. 1989;27 Suppl 1:79S-85S.

35.

Pharmacokinetics of vigabatrin: implications of creatinine clearance.

Haegele KD, Huebert ND, Ebel M, Tell GP, Schechter PJ.

Clin Pharmacol Ther. 1988 Nov;44(5):558-65.

PMID:
3180638
36.

Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy.

Menachem EB, Persson LI, Schechter PJ, Haegele KD, Huebert N, Hardenberg J, Dahlgren L, Mumford JP.

Epilepsy Res. 1988 Mar-Apr;2(2):96-101.

PMID:
3143561
37.

2-Pyrrolidinone in human cerebrospinal fluid: a major constituent of total gamma-aminobutyric acid.

Haegele KD, Schwartz JJ, Schoun J, Schmitt AH, Schechter PJ.

J Neurochem. 1987 Nov;49(5):1402-6.

PMID:
3668531
38.

Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire.

Doua F, Boa FY, Schechter PJ, Miézan TW, Diai D, Sanon SR, De Raadt P, Haegele KD, Sjoerdsma A, Konian K.

Am J Trop Med Hyg. 1987 Nov;37(3):525-33.

PMID:
3120607
39.

Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients.

Taelman H, Schechter PJ, Marcelis L, Sonnet J, Kazyumba G, Dasnoy J, Haegele KD, Sjoerdsma A, Wery M.

Am J Med. 1987 Mar 23;82(3 Spec No):607-14.

PMID:
3103442
40.

Decarboxylated-S-adenosylmethionine excretion: a biochemical marker of ornithine decarboxylase inhibition by alpha-difluoromethylornithine.

Haegele KD, Splinter TA, Romijn JC, Schechter PJ, Sjoerdsma A.

Cancer Res. 1987 Feb 1;47(3):890-5.

41.

Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer.

Haegele KD, Schechter PJ.

Clin Pharmacol Ther. 1986 Nov;40(5):581-6.

PMID:
3769388
42.

Electrophysiological effects of intravenous MDL 17.043.

Pop T, Treese N, Cremer GM, Haegele KD, Meyer J.

Int J Cardiol. 1986 Aug;12(2):223-32.

PMID:
2943683
43.

Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA-transaminase inhibitor.

Saletu B, Grünberger J, Linzmayer L, Schwartz JJ, Haegele KD, Schechter PJ.

Int J Psychophysiol. 1986 May;4(1):63-80.

PMID:
3721943
44.

GABA differentially regulates the gene expression of proopiomelanocortin in rat intermediate and anterior pituitary.

Loeffler JP, Demeneix BA, Pittius CW, Kley N, Haegele KD, Höllt V.

Peptides. 1986 Mar-Apr;7(2):253-8.

PMID:
3737446
46.

Pharmacokinetics of piroximone (MDL 19.205) in healthy volunteers.

Haegele KD, Belz GG, Meinicke TT, Schechter PJ.

Eur J Clin Pharmacol. 1986;31(2):239-42.

PMID:
3803422
47.

Evidence against putrescine and polyamines as endogenous mediators of fever.

Dascombe MJ, Haegele KD.

J Pharm Pharmacol. 1985 May;37(5):365-6.

PMID:
2862252
48.

Kinetics of fenoximone, a new cardiotonic, in healthy subjects.

Alken RG, Belz GG, Haegele KD, Meinicke T, Schechter PJ.

Clin Pharmacol Ther. 1984 Aug;36(2):209-16.

PMID:
6235081
49.

Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist.

Haegele KD, Jaillon P, Cheymol G, Alken RG, Schechter PJ, Koch-Weser J.

Clin Pharmacol Ther. 1983 Dec;34(6):785-91.

PMID:
6641094
50.

Hemodynamic effects of MDL 17,043, a new cardiotonic agent, in patients with congestive heart failure: comparison with sodium nitroprusside.

Arbogast R, Brandt C, Haegele KD, Fincker JL, Schechter PJ.

J Cardiovasc Pharmacol. 1983 Nov-Dec;5(6):998-1004.

PMID:
6196573

Supplemental Content

Loading ...
Support Center